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Abstract
Background. Many factors affect survival in haemodialy-
sis (HD) patients. Our aim was to study whether quality of
clinical caremay affect survival in this population, when ad-
justed for demographic characteristics and co-morbidities.
Methods. We studied survival in 553 patients treated by
chronic HD during March 2001 in 21 dialysis facilities
in western Switzerland. Indicators of quality of care were
established for anaemia control, calcium and phosphate
product, serum albumin, pre-dialysis blood pressure (BP),
type of vascular access and dialysis adequacy (spKt/V) and
their baseline values were related to 3-year survival. The
modified Charlson co-morbidity index (including age) and
transplantation status were also considered as a predictor of
survival.
Results. Three-year survival was obtained for 96% of the
patients; 39% (211/541) of these patients had died. The 3-
year survival was 50, 62 and 69%, respectively, in patients
who had 0–2, 3 and ≥4 fulfilled indicators of quality of
care (test for linear trend, P < 0.001). In a Cox multivari-
ate analysis model, the absence of transplantation, a higher
modified Charlson’s score, decreased fulfilment of indica-
tors of good clinical care and low pre-dialysis systolic BP
were independent predictors of death.
Conclusion. Good clinical care improves survival in HD
patients, even after adjustment for availability of transplan-
tation and co-morbidities.
Keywords: co-morbidity score; end-stage renal failure;
haemodialysis; quality of care; survival
Introduction
Survival in patients with end-stage renal failure (ESRF)
treated by chronic dialysis is notoriously poor. For example,
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in Europe, survival rates are 82% at 1 year and 47% at
5 years [1]. Some of the excess mortality in haemodialysis
(HD) patients is due to the high prevalence of cardiovascu-
lar and other co-morbidities, but the quality of care they re-
ceive is also critical. Dialysis practice guidelines have been
developed and disseminated [2–4] and systematic measure-
ments of clinical performance, relying on indicators such
as levels of Kt/V, haematocrit and serum albumin, have
been implemented. These indicators reflect the quality of
relevant health care processes (i.e. amount of dialysis, treat-
ment of anaemia, nutritional level) and they correlate with
patient mortality and morbidity [5–8].
However, most studies of patient survival conducted to
date did not account for all relevant quality of care cri-
teria and patient characteristics. Furthermore, the relative
importance of quality of care and patient characteristics
for patient survival is not well understood. The impact of
attaining multiple performance targets has been evaluated
recently in two observational studies in prevalent and in-
cident patients, where mortality and hospitalization rates
were higher with increasing number of unfulfilled thera-
peutic targets in a dose-dependent manner [9,10]. In addi-
tion to quality of care, patient characteristics such as age,
gender, body mass index (BMI) and blood pressure (BP)
may also affect survival. Recently, a simple co-morbidity
score, the modified Charlson co-morbidity index, has been
validated in the dialysis population [11].
The aim of this study was to identify whether good clini-
cal care affects survival in HD patients after adjustment for
the modified Charlson co-morbidity index, gender, BMI,
kidney transplantation and duration of renal replacement
therapy.
Subjects and methods
Study design and population
This prospective study is based on the cohort of all ESRF
patients haemodialyzed in western Switzerland for whom
a detailed assessment of quality of care was performed
in March 2001 [12]. This project was approved by the
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For Permissions, please e-mail: journals.permissions@oxfordjournals.org
1976 P. Saudan et al.
research ethics committees of the Universities of Lausanne
and Geneva.
Study variables
The dependent variable was survival between March 2001
and April 2004.
Variables used as quality criteria for individual patients
were recorded in six domains of clinical care:
1. Dialysis adequacy: for HD patients, the single pool (sp)
Kt/V was calculated using the sp Daugirdas II method
based on post-dialysis plasma samples drawn after
slowing the blood pump to 50 mL/min for 2 min. A
sp Kt/V ≥ 1.2 was considered adequate.
2. Appropriate anaemia management: assessed by
achieved haemoglobin levels. When several measures
were recorded during the past month, the average was
used for the determination. A haemoglobin ≥110 g/L or
a haematocrit ≥33% was considered adequate.
3. Calcium and phosphate metabolism: assessed by the
calcium–phosphate product. A value of<4.4 mmol2/L2,
using pre-dialysis serum calcium and phosphorus levels,
was considered adequate.
4. Nutrition: assessed by the serum albumin. A level
>35 g/L was considered to be a criterion of good
nutrition.
5. Vascular access: defined by the presence of a native ar-
teriovenous fistula (AVF), a synthetic graft or a catheter.
Dialysis via a native AVF was considered optimal.
6. Hypertension control: assessed by the mean pre-dialysis
BP over 1 week. Hypertension was defined as the mean
pre-dialysis BP >140/90 over 1 week.
Additional predictor variables were patient age, gender,
cause of renal failure, time on renal replacement ther-
apy, type of membranes (an in vitro ultrafiltration coef-
ficient>20 mL/min was used to separate between low-flux
and high-flux membranes), pre-dialysis nephrologist refer-
ral (referral <1 month prior to HD implementation was
defined as late), placement on waiting list for transplanta-
tion, actual transplantation and presence of medical con-
ditions that allow computation of the modified Charlson
co-morbidity index [11]. This index scored l for all forms of
coronary artery disease as well as congestive heart failure,
peripheral vascular and cerebrovascular diseases, demen-
tia, chronic pulmonary disease, connective tissue disorder,
peptic ulcer disease, mild liver disease and diabetes. Haemi-
plegia, diabetes with organ damage, any tumour, leukaemia
and lymphoma were scored 2. Moderate or severe liver dis-
ease was scored 3 and AIDS or metastatic solid tumour
was scored 6. We added 2 points for ESRF and 1 for each
decade>40 years of age. This modified index was recently
validated for predicting outcomes and costs in dialysis pa-
tients [11]. We stratified the modified Charlson score into
three levels (2–5, 6–9 and >9).
Data collection
At baseline, patient-level data were collected by means of
a questionnaire completed by the centre team based on
each patient’s medical and nursing records. Data on 3-year
survival and transplantation were subsequently obtained for
these patients by referring to their medical records.
Data analysis
Descriptive statistics were used to represent demographic
and clinical characteristics of the study population.
Variables used as indicators of good clinical care were
dichotomized as being or not in conformity with the desired
range set by the guidelines as reference value. As there was
no difference in 3-year survival between native fistulas and
grafts (63% versus 68%), both types were grouped together
and compared to catheters. We examined the relationships
between each indicator and survival in Cox proportional
hazards models as follows: (a) unadjusted associations (i.e.
hazard ratios), (b) associations adjusted for patient char-
acteristics and (c) associations adjusted for other quality
indicators and for patient characteristics. We also grouped
the number of fulfilled quality indicators into three strata
(0–2, 3 and ≥4), and constructed a comprehensive model
that included this variable and all other relevant predictors.
Transplanted patients were censored (i.e. removed from the
analysis of mortality) at the time of transplantation, except
for the last model (Table 3) where transplantation was used
as a time-dependent variable. In the latter model, time be-
fore transplantation was used to compute the mortality risk
of non-transplanted patients, and time after transplantation
to compute mortality risk in transplanted patients. As low
pre-dialysis systolic BP (SBP) in patients without any anti-
hypertensive medications was associated with a poor 3-year
survival, it was included in the Cox proportional hazards
analysis.
Survival curves were obtained by the Kaplan–Meier
method and compared with the log-rank test. All data analy-
ses were performed using SPSS forWindows (version 11.0,
Chicago, IL, USA).
Results
Data collection
Baseline data were obtained between March and June 2001
for all patients treated by HD (n = 553) in all 21 centres
in western Switzerland from centre nurses and nephrolo-
gists. Three-year survival data were obtained for 541 (98%)
patients.
Patient characteristics at baseline
Almost all patients (98%) were Caucasian; a slight major-
ity was male and the mean age was 64 years (Table 1).
Hypertensive nephropathy was the leading cause of ESRD
(end-stage renal disease), and vascular disease was themost
prevalent co-morbid condition. Diabetes was diagnosed as
the main cause of ESRD in 15% of our patients but when
included as a co-morbidity factor, it was present in nearly
one-third of them. The mean modified Charlson index (in-
cluding age) was 7.6 (SD3.1).
Two out of five patients were referred late for dialy-
sis (Table 1). The median duration of renal replacement
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Table 1. Demographic, clinical and treatment characteristics of HD patients in western Switzerland (March 2001)
Patients (n) 541
Age (year, mean ± SD) 64 ± 15
Patients >70 years old (%) 39.9
Male gender (%) 63
Late referral (%) 37.8
Causes of renal failure: (%)
HTN 32
Diabetes (unique diagnosis) 14
Glomerulonephritis 14
Vasculitis 5
Interstitial nephritis 11
PCKD 13
Others 11
Smokers (%) 20
Physical disability (%) 17
Cerebrovascular/coronary/ heart/peripheral vascular disease (%) 53
Cancer (%) 14
Diabetes (%) 28
Body mass index between 20 and 25 (%) 48
Body mass index<20 (%) 14
Modified Charlson co-morbidity index (mean ± SD, range) 7.6 ± 3.1, 2–19
Patients wait-listed for transplantation (%) 21
Renal replacement therapy duration (year, median and IQR range) 3 (1–6.5)
Haemodialysis time (min, mean ± SD) 218 (37)
Biocompatible (synthetic) dialyser membranes (%) 90
Prevalence of high-flux membranes (%) 73
RhuEpo use (%) 90
Vitamin D use (%) 50
Calcium-based phosphate binders (%) 85
Aluminium salts (%) 17
ACE-inhibitors/angiotensin II antagonists use (%) 35
Beta-blockers use (%) 26
Native arteriovenous fistula/grafts/permanent catheters/temporary catheters (%) 58/22/13/7
spKt/V (mean ± SD) 1.37 ± 0.3
Haemoglobin (g/L) (mean ± SD) 118 ± 14
Phosphocalcic product (mmol2/L2) (mean ± SD) 3.9 ± 1.14
Serum albumin (g/L) (mean ± SD) 36.2 ± 5.9
HTN control (mean pre-dialysis BP<140/90) (%) 38
therapy was 3 years. The mean HD time was 218
min/session. Seventy-three percent of the patients had dial-
ysis with high-flux membranes. Eighty percent had an AVF
(Table 1). Mean Kt/V, albumin, haemoglobin and calcium–
phosphate product are listed in Table 1.
Three-year survival
At 3 years of follow-up, 211 out of the 541 HD patients had
died. Among the 108 patients on the waiting list, 63 were
successfully transplanted. Three-year survival for trans-
planted patients, patients still wait-listed for transplantation
and patients not wait-listed was 97% (68/70), 79% (30/38)
and 54% (232/433), respectively.
Quality indicators and mortality
When looked at one by one, the only criterion of quality of
care that remained highly significant for survival was the
presence of a fistula, after adjusting for case-mix and other
indicators of good clinical care (Table 2). In groups that
fulfilled 0–2, 3 and >4 criteria, fistula prevalence was 49,
86 and 96%, respectively. In order to determine the impact
of AVF, the Cox model with quality criteria (without fis-
tula) categorized into 0–2-, 3- and 4–5-fulfilled indicators
(reference) gives rather similar results when the fistula was
added as an independent predictor. With fistula, the HR for
0–2- and 3-fulfilled criteria were 1.92 (95% CI 1.38–2.67,
P = 0.001) and 1.09 (95% CI 0.77–1.55, P = 0.62), re-
spectively. Without fistula, the HR for 0–2- and 3-fulfilled
criteria were 1.73 (95% CI 1.19–2.52, P = 0.004) and 1.07
(95% CI 0.75–1.52, P = 0.71), respectively.
However, there was an increased survival with the attain-
ment of indicators of good clinical care, as the 3-year rates
were 50% (70/139), 62% (96/156) and 69% (165/240) in
HD patients who had 0–2-, 3- and >4-attained indicators,
respectively (Figure 1).
In the final multivariate analysis, the absence of trans-
plantation, increased co-morbidity score (including age),
absence of AVF, presence of SBP<110 mmHg and non-
conformity to quality criteria remained independent pre-
dicting factors for death (Table 3). BMI between 26 and 29
was associated with a reduction in mortality (Table 3). We
observed a trend for better survival with the use of high-
flux membranes, which however did not reach statistical
significance (Table 3). The adjusted effect of sub-optimal
clinical quality (defined by <2-fulfilled quality criteria)
was to increase mortality by 1.8-fold. This result differed
somewhat by theCharlson score (CS 2–5:HR2.60, 95%CI:
1.00–6.75, P= 0.05; CS 6–9: HR 1.63, 95% CI: 1.07–2.49,
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Table 2. Relationships between quality of care indicators and survival of haemodialyzed patients in western Switzerland
Patients Percentage Unadjusted Each quality indicator adjusted Each quality indicator adjusted
for case mixa for other indicators and case mixa
HR (95% CI) HR (95% CI) HR (95% CI)
Albumin (g/L)
>35 64 1.0 1.0
30–35 24 0.71 (0.48–1.06) 1.11 (0.80–1.55) 1.06 (0.75–1.49)
<30 12 0.81 (0.35–0.81) 1.17 (0.78–1.74) 0.98 (0.65–1.50)
Haemoglobin (g/L)
110–120 (or Hct 33–36%) 27 1.0 1.0 1.0
>120 (or Hct > 36%) 47 0.82 (0.56–1.19) 1.12 (0.79–1.59) 1.17 (0.82–1.66)
<110 (or Hct < 33%) 26 0.86 (0.62–1.20) 1.26 (0.86–1.84) 1.25 (0.86–1.84)
P × Ca product (mmol2/L2) 42 1.0 1.0 1.0
3.2–4.4 25 1.14 (0.82–1.59) 1.02 (0.72–1.44) 0.97 (0.69–1.38)
<3.2 33 1.28 (0.89–1.85) 0.93 (0.67–1.30)
>4.4 0.93 (0.66–1.29)
SBP (mmHg)
110–150 57 1.0 1.0 1.0
>150 39 1.15 (0.86–1.53) 0.98 (0.73–1.32) 0.94 (0.70–1.27)
<110 5 2.47 (1.43–4.24) 2.35 (1.36–4.05) 2.19 (1.22–3.92)
DBP (mmHg)
70–90 64 1.0 1.0 1.0
>90 14 0.65 (0.48–0.90) 1.02 (0.66–1.59) 0.92 (0.58–1.46)
<70 22 0.66 (0.41–1.06) 1.57 (1.14–2.16) 1.62 (1.17–2.24)
spKt/V
>1.2 76 1.0 1.0 1.0
1–1.2 16 1.41 (0.97–2.05) 1.17 (0.80–1.71) 1.17 (0.79–1.73)
<1 9 1.40 (0.87–2.24) 1.32 (0.82–2.12) 1.22 (0.75–1.98)
Presence of fistula 81 0.64 (0.46–0.87) 0.61 (0.44–0.84) 0.66 (0.47–0.92)
Quality of care indicators fulfilled:
>4 45 1.0 1.0 1.0
3 29 1.29 (0.91–1.81) 1.14 (0.81–1.61) 1.29 (0.86–2.48)
0–2 26 1.92 (1.39–2.66) 1.80 (1.29–2.50) 2.81 (1.17–6.77)
aModified Charlson’s co-morbidity index, gender, body mass index and years of renal replacement therapy.
Fig. 1. Three-year survival curves according to the numbers of fulfilled
indicators of quality of care in HD patients of western Switzerland (log
rank 16.2, P = 0.0003).
P = 0.02; CS> 9: HR 1.90, CI: 1.21–2.98, P = 0.005) but
these differences were not significant (P = 0.66).
Three-year survival curves established for groups of co-
morbidity scores showed a decrease from 89% (score 2–5)
to 36% (score>9) (Figure 2).
Discussion
Our study shows that good clinical care, assessed by
clinical performance targets, is positively associatedwith 3-
year survival in patients on HD. This effect is independent
of patient characteristics, including their co-morbidities.
Nearly half of our patients had ≥4-attained quality of care
indicators and we could show that their death rate is sig-
nificantly associated with decreasing number of quality
of care indicators attained 3 years earlier (Figure 1 and
Table 3).
Our results are in agreement with those of two re-
cently published studies that studied the short-term im-
pact of attaining similar clinical performance targets [9,10].
These targets were: haemoglobin (≥11 g/dL), dialysis dose
(Kt/V ≥ 1.2), albumin (≥4.0 g/dL) and presence of a native
AVF. Calcium–phosphate product (≤4.4 mmol2/L2) was
also considered as a clinical performance measure in the
study of the CHOICE cohort where 668 incident HD pa-
tients had a prospective median follow-up of 2.8 years. At
6 months after enrolment in the study, attainment of each
of the five targets studied was associated with a decreased
mortality and morbidity [9]. This decrease was also pro-
portional to the number of attached targets, irrespective
of which target was met. Within the ESRD Clinical Perfor-
manceMeasures Project, 15 287 prevalentHDpatientswere
studied and 1-year mortality decreased progressively from
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Table 3. Univariate and multivariate analyses (with transplantation as a time-dependant variable) of predictive factors for death among haemodialyzed
patients in western Switzerland (March 2001)
Percentage Univariate HR (95% CI) P Multivariate HR (95% CI) P
Fulfilled indicators of quality of care:
4–6 45 1.0 1.0
3 29 1.30 (0.93–1.81) 0.13 1.10 (0.78–1.56)
0–2 26 1.85 (1.34–2.56) 0.001 1.91 (1.38–2.65)
No transplantation 13 10.40 (2.58–41.99) 0.001 7.27 (1.79–29.50) 0.006
Late referral 38 1.05 (0.79–1.38) 0.75 0.99 (0.75–1.33) 0.98
Male gender 63 1.14 (0.86–1.50) 0.36 1.24 (0.93–1.65) 0.15
BMI
20–25 54 1.0 1.0 1.0
<20 11 1.15 (0.76–1.73) 0.52 0.98 (0.64–1.50) 0.93
26–29 21 0.72 (0.49–1.04) 0.08 0.61 (0.42–0.90) 0.60
>29 14 0.91 (0.61–1.38) 0.66 0.89 (0.58–1.37) 0.1
Modified Charlson’s score
2–5 24 1.0 1.0 1.0
6–9 49 3.45 (2.07–5.77) 0.001 3.38 (1.99–5.71) 0.001
>9 27 7.06 (4.21–11.86) 0.001 7.19 (4.20–12.29) 0.001
RRT (years) 0.99 (0.98–1.02) 0.84 1.01 (0.99–1.04) 0.28
Low pre-dialysis SBP (<110 mmHg) 5 2.24 (1.33–3.80) 0.003 2.44 (1.43–4.16) 0.001
High flux (versus low flux) 73 0.68 (0.51–0.91) 0.009 0.79 (0.59–1.06) 0.12
Fig. 2. Three-year survival curves according to modified Charlson’s co-
morbidity scores in HD patients of western Switzerland (log rank 63.7,
P < 0.001).
29 to 7% with an additional attainment of 0–4 targets [10].
Partial adjustment was made for patients’ co-morbidities
and follow-up was relatively short in this study [10]. How-
ever, our results confirmed that attainment of clinical per-
formance targets in prevalent patients after adjustment for
their co-morbidities was also associated with a decrease
in mortality. The presence of fistula was the only isolated
indicator of good clinical care that was associated with a
significant decline in the 3-year mortality (Table 2). Among
the different types of vascular accesses, AVF is known to
have fewer complications than grafts or tunnelled perma-
nent catheters. Nevertheless, the latter are increasingly em-
ployed because of an aging dialysis population with less
usable vessels and more at risk of AVF primary failure. A
50% higher mortality was found in incident patients not
dialyzed with AVF [13].
More than one-third of our patients were referred within
<1 month of starting dialysis. Although late referral in our
population was not associated with a decreasing 3-year sur-
vival, this late referral has been associated with increasing
catheter use [14]. Only upstream strategies aimed at iden-
tifying the candidates earlier so that their venous network
could be spared will maximize the number of patients with
AVF.
Of the other factors associated with death, absence of
transplantation, overweight, low pre-dialysis BP and co-
morbidities (including age) remained significant predictive
factors of death in HD patients. The positive impact of
transplantation in our patients is in agreement with what is
currently found in the medical literature [15,16].
Overweight HD patients have been found to have a
greater survival than their leaner counterparts [7,17] and
our patients with a BMI between 26 and 29 had a 3-year
mortality that was 39% lower than their counterparts with a
BMI ranging between 20 and 25. A higher BMI was, how-
ever, not statistically significant in ourmultivariate analysis.
Though we cannot exclude a type II error, it is likely that
compared to a North American HD population, there is a
narrower range of BMI values in our population with 73%
of our patients between 20 and 29.
Hypertension is one of the major cardiovascular risk fac-
tors, but low pre-dialysis BP predicts increased mortality
in observational studies [18,19]. As with obesity, the phys-
iopathology underlying the association between mortality
and low BP remains elusive, although this changes over
time with low BP being especially harmful within the first
2 years of dialysis and high BP after 2 years [18,20]. Low
mean arterial pressure was a strong predictor of death in our
population. Although we cannot exclude that the patients
with low BP were sicker, their demographic characteristics
and mean Charlson score were not different from patients
with higher pre-dialysis BP (data not shown). Achieving dry
weight in patients with low BP may be difficult and these
patients are more prone to dialysis-associated hypotension
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with subsequent increasing morbidity. The physiopathol-
ogy of the negative impact of low BP in HD patients needs
to be better understood, so that a more specific therapeutic
approach can be devised.
A low serum albumin is a marker of poor clinical con-
dition and/or poor nutritional status and is associated with
subsequent increasing mortality in HD patients [8,21]. Ad-
justment for co-morbidities other than diabetes was not
done in these previous studies. In our patients, serum al-
bumin <30 g/L was not significantly associated with mor-
tality after adjustment for other risk factors. Conflicting
results have been found in previous studies on the bene-
ficial impact of using high-flux membranes. We found a
beneficial effect of high-flux membranes that just fell short
of statistical significance. A similar effect was observed
among French patients, whose mean dialysis duration was
102 months; those treated with high-flux membranes ex-
perienced a 40% reduction in the 2-year mortality [22]. In
contrast, no difference of mortality between patients treated
either by low-fluxHD or by high-fluxHD has been reported
in the DOPPS study [23]. Use of high-flux membranes was
not found to have a significant impact on mortality ex-
cept for patients with transplantation vintage>3.7 years of
dialysis in the HEMO study [24].
Associated co-morbidities heavily determine the fate of
our patients [21] and measuring them is of importance, as
this treatment is lifesaving but very expensive.
The Charlson co-morbidity index has been validated
in the dialysis population with some minor modifications
[11,16,25]. In our patients, duration of survival was in-
versely related to their Charlson scores (Figure 2). Though
co-morbidities do not fully explain the difference in mor-
tality among the American, European and Japanese pa-
tients and their impact after adjustment for age, gender
and race is lower than expected [26,27], a simple and
easy-to-use co-morbidity score could be useful for clinical
decision-making. Its usemay help to determine a successful
long-term implementation of dialysis especially for elderly
patients, whose number has been rising in the past decade
[28]. However, the Charlson score needs to be validated
first in an incident HD population in the elderly prior to the
generalization of its use.
Our study has some limitations. This longitudinal study
did not have serial repeated measurements and it is likely
that our indicators of quality of care and some dialysis-
related characteristics such as membranes or weekly dial-
ysis time for patients treated by chronic HD may have
changed throughout the follow-up time. This is an observa-
tional study allowing us to measure associations between
clinical factors and survival, but which cannot demonstrate
any causal relationship. Our patients had in this survey
an unadjusted 3-year survival rate of 61%, which is rela-
tively similar to the 3-year survival rate of 65% for inci-
dent HD patients reported in the annual report 2002 ERA–
EDTA registry [1]. However, there was a predominance of
Caucasians in our population and an extrapolation of our
results to multiracial societies other than European may not
be possible.
In summary, our results show that the attainment of tar-
gets set by the guidelines to improve quality of care increase
survival in our HD patients after adjustment for case mix.
Importantly, the use of a catheter, as opposed to a fistula,
was associated with shorter survival. Similarly, low pre-
dialysis BP also predicted shorter survival. These results
suggest that changes to pre-dialysis care and dialytic proce-
dures, such as shifting to short daily dialysis or night-long
dialysis in order to overcome hypotension-related dialysis
difficulties, may ultimately improve survival.
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